MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy

Summary

This phase II trial is studying how well MK2206 works in treating patients with advanced liver cancer that did not respond to previous therapy. MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2010-12

Primary completion

2013-02

Completion

2013-02

Drugs

Indications